Editing Valproate (section)

== Research ==
A 2023 systematic review of the literature identified only one study in which valproate was evaluated in the treatment of seizures in infants aged 1 to 36 months. In a randomized control trial, valproate alone was found to show poorer outcomes for infants than valproate plus levetiracetam in terms of reduction of seizures, freedom from seizures, daily living ability, quality of life, and cognitive abilities.<ref>{{Cite report |vauthors=Treadwell JR, Wu M, Tsou AY |date=October 2022 |title=Management of Infantile Epilepsies |url=https://effectivehealthcare.ahrq.gov/products/management-infantile-epilepsy/research |access-date=12 July 2023 |website=effectivehealthcare.ahrq.gov |language=en |doi=10.23970/ahrqepccer252 |pmid=36383706 |location=Rockville (MD) |publisher=Agency for Healthcare Research and Quality (US) |id=Report No.: 22(23)-EHC004 Report No.: 2021-SR-01 |archive-date=5 July 2023 |archive-url=https://web.archive.org/web/20230705073433/https://effectivehealthcare.ahrq.gov/products/management-infantile-epilepsy/research |url-status=live |url-access=subscription }}</ref>